In this podcast with Pharmaceutical Commerce, Atul Vashistha discusses supply chain risk in the pharma industry.
With a new administration in the White House, supply chain leaders must consider what will change!
The Black Swan by Nassim Nicholas Taleb seemed to explain much about “the impact of the highly improbable.”
In this article, experts warn about potential supply chain risks that the 100-day review will uncover.
U.S. financial regulators are stepping up their oversight of ESG issues.
Even before COVID materialized, traditional TPRM practices were struggling to keep pace.
Risk is a raindrop before it is a waterfall. Adopt an “always-on” approach to risk.